Mantle Cell Lymphoma Videos

Videos

Promising Advances in the Mantle Cell Lymphoma Treatment Landscape

02/13/2024

Featuring Eliza A Hawkes, MD

Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.

Eliza A Hawkes, MD, shares some...

02/13/2024

Oncology

Conference Coverage

Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape

01/08/2024

Featuring Bijal D. Shah, MD

Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.

Bijal D. Shah, MD, shares the...

01/08/2024

Oncology

Videos

Real-World BTK Inhibitor Utilization and Outcomes Following Discontinuation in Older Patients With MCL

12/14/2022

Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.

Mengyang Di, MD, PhD, discussed...

12/14/2022

Journal of Clinical Pathways

Videos

Frontline Therapies for Patients With Untreated and Relapsed Mantle Cell Lymphoma

09/14/2022

Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.

Tycel Phillips, MD, reviews...

09/14/2022

Journal of Clinical Pathways

Videos

Real-World Treatment Patterns and Outcomes Among Patients With Mantle Cell Lymphoma

07/21/2022

Mayur Narkhede, MD, analyzed treatment patterns among patients with mantle cell lymphoma at different lines of therapy, focusing on BTKi use, and compared outcomes with known prognostic factors.

Mayur Narkhede, MD, analyzed...

07/21/2022

Journal of Clinical Pathways

Videos

Real-World Effectiveness of Rituximab Maintenance Among Older Patients With Mantle Cell Lymphoma

06/15/2022

Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.

Mengyang Di, MD, PhD, evaluates...

06/15/2022

Journal of Clinical Pathways

Videos

Real-World Treatment Patterns of Bruton Tyrosine Kinase Inhibitors Among Patients With Mantle Cell Lymphoma

06/14/2022

Bijal Shah, MD, discusses his study which assessed patient characteristics, treatment patterns and associated outcomes in real-world BTKi-treated patients with MCL.

Bijal Shah, MD, discusses his...

06/14/2022

Journal of Clinical Pathways

Peter Martin, MD, Weill Cornell Medicine

Videos

Real-World Treatment Patterns and Outcomes Among Patients With MCL

08/20/2021

Peter Martin, MD, real-world treatment patterns and outcomes among 3455 patients with previously untreated MCL in the United States.

Peter Martin, MD, real-world...

08/20/2021

Journal of Clinical Pathways

Videos

Bendamustine Plus Rituximab Safe, Effective for Treating MCL in Real-World Setting

07/15/2021

Rouslan Kotchetkov, MD, PhD, discusses results from a retrospective review exploring the efficacy and safety of bendamustine plus rituximab for the treatment of MCL in the real-world setting.

Rouslan Kotchetkov, MD, PhD,...

07/15/2021

Journal of Clinical Pathways

Sponsored

Videos

Physician Testimonial With Dr. Goy (Sponsored)

02/11/2021

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Mantle Cell Lymphoma Videos

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products